Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $63,623.40 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 55,810 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $1.14, for a total transaction of $63,623.40. Following the sale, the insider directly owned 5,731,860 shares of the company’s stock, valued at $6,534,320.40. The trade was a 0.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Monday, November 10th, Bioventures 2014 L.P. Mpm sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total value of $57,312.60.
• On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $65,886.92.
• On Wednesday, November 5th, Bioventures 2014 L.P. Mpm sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $58,499.00.
• On Tuesday, November 4th, Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $171,395.36.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total transaction of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.

Werewolf Therapeutics Trading Down 1.0%

Shares of NASDAQ:HOWL opened at $0.92 on Friday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38. The stock has a market cap of $44.57 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. The business has a 50-day moving average price of $1.57 and a 200-day moving average price of $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on HOWL shares. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Finally, Bank of America decreased their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently bought and sold shares of HOWL. Quadrature Capital Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $28,000. Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at about $48,000. Nuveen LLC acquired a new stake in Werewolf Therapeutics during the first quarter worth about $71,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics during the first quarter worth about $79,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $92,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.